| Source: HalifaxProj (inhibit) CGL-Driver Genes |
| Type: Antiapoptotic Oncogene |
| The proteins of BCL-2 family are classified into three subgroups, i.e., the anti-apoptotic/pro-survival proteins represented by BCL-2 and BCL-XL, the pro-apoptotic proteins represented by BAX and Bak, and the pro-apoptotic BH3-only proteins represented by BAD and BID. Since the expression of Bcl-2 protein in tumor cells is much higher than that in normal cells, inhibitors targeting it have little effect on normal cells. |
| Hepatoma: usually malignant tumor occurring in the liver. |
| 385- | AgNPs, | Probiotic-derived silver nanoparticles target mTOR/MMP-9/BCL-2/dependent AMPK activation for hepatic cancer treatment |
| - | in-vitro, | Hepat, | HepG2 | - | in-vitro, | Hepat, | WI38 |
| 406- | CUR, | Effect of curcumin on normal and tumor cells: Role of glutathione and bcl-2 |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Hepat, | HepG2 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:11 Cells:% prod#:% Target#:27 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid